No abstract available.

No abstract available.
Adult* ; Humans ; Life Style*

No abstract available.
Anticoagulants* ; Venous Thromboembolism*

No abstract available.
Protein Kinases

No abstract available.
Diagnosis* ; Humans ; Venous Thromboembolism*

No abstract available.
Diagnosis* ; Humans ; Venous Thromboembolism*

No abstract available.
Phenytoin* ; Stevens-Johnson Syndrome*

The nationwide statistical analysis of each disease of classical myeloproliferative neoplasm (MPN) in Korea has not been reported yet. To this end, we have analyzed incidence rates, survival rates and treatment pattern of polycythemia vera (PV), primary myelofibrosis (MF) and essential thrombocythemia (ET) using Korea National Cancer Incidence Database (KNCIDB) and Health Insurance Review and Assessment Service (HIRA) database. Between 2003 and 2011, a total of 4,342 new cases of MPN were reported to the KNCIDB. ET was the most common, followed by MF and PV. The crude incidence rates for PV, MF, and ET have increased during the period, reaching 0.40, 0.15, and 0.84 per 100,000, respectively. Five-year relative survival rate of all MPN patients was 89.3%, with lowest relative survival rate with MF (53.1%). The prevalence of each disease estimated from HIRA data also increased during the study period. Notably, ET was found to be most prevalent. The prescription rate of hydroxyurea and phlebotomy to PV, MF and ET patients remained constant over the period, and the prescription rate of hydroxyurea was higher in patients with age over 60 years. This is the first Korean nationwide statistics of MPN, using central registry data. This set of data can be utilized to compare the Korean MPN status to international data and guidelines.
Humans ; Hydroxyurea ; Incidence* ; Insurance, Health ; Korea* ; Phlebotomy ; Polycythemia Vera ; Prescriptions ; Prevalence* ; Primary Myelofibrosis ; Survival Rate ; Thrombocythemia, Essential

Venous thrombosis in atypical locations means thrombosis of upper extremity deep vein, cerebral venous sinus, splanchnic vein including portal, hepatic, mesenteric and splenic vein, renal vein, ovarian vein and retinal vein. This thrombosis rarely occurred and could be affected by the involved organ when compared to the incidence and cause of deep vein thrombosis in lower extremity with or without pulmonary embolism. There is a limitation to perform a large-scaled randomized trial for these rare conditions, and several recommendations based on results of small-sized studies and observational registries are available now. Therefore, we need multi-department and international collaboration to test the efficacy and safety of anticoagulation including new oral anticoagulants in the treatment of venous thrombosis in atypical locations.
Anticoagulants ; Budd-Chiari Syndrome ; Cerebral Veins ; Cooperative Behavior ; Incidence ; Lower Extremity ; Pulmonary Embolism ; Registries ; Renal Veins ; Retinal Vein ; Splenic Vein ; Thrombosis ; Upper Extremity ; Upper Extremity Deep Vein Thrombosis ; Veins ; Venous Thrombosis*

Cancer-associated venous thromboembolism (CAT) is a common complication associated with high morbidity and mortality. In accordance with major clinical trials comparing low-molecular-weight heparin (LMWH) with a vitamin K antagonist (VKA), LMWH is currently the standard treatment for CAT, owing to its efficacy for thrombosis recurrence and improved safety profile compared to VKA. Over the past few years, direct oral anticoagulants (DOACs) have emerged as potential alternative therapies to LMWH due to their convenient route of administration and predictable pharmacokinetics, but evidence for their use in CAT is inconclusive, as only a small fraction of the study populations in these trials had CAT. Recently, two large head-to-head trials comparing DOACs to LMWH in CAT patients reported comparable efficacies of DOACs with increased bleeding risk. Occasionally, CAT treatment can be challenging due to the heterogeneity of underlying malignancies and comorbidities. Renal insufficiency and gastrointestinal defects are the main obstacles in anticoagulant selection. Careful choice of treatment candidates and proper anticoagulant strategies are critical for the treatment of CAT; hence, more studies are required to address these challenges.
Animals ; Anticoagulants ; Cats ; Comorbidity ; Complementary Therapies ; Hemorrhage ; Heparin, Low-Molecular-Weight ; Humans ; Mortality ; Pharmacokinetics ; Population Characteristics ; Recurrence ; Renal Insufficiency ; Thrombosis ; Venous Thromboembolism ; Vitamin K